Evidence map›Paper›PMID 40165956›Full record

ArticleFrontiers in immunology2025

Immunoglobulin G

Huachen Wang, Houqiang Li, Zheng Guo, Hongda Hou, Haifeng Hou, Bing Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Immunoglobulin GFrontiers in immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huachen Wang *Institute of Infectious Diseases, The Second Hospital of Tianjin Medical University, Tianjin, China.
Houqiang Li *Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Zheng Guo *Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
Hongda HouInstitute of Infectious Diseases, The Second Hospital of Tianjin Medical University, Tianjin, China.
Haifeng HouSchool of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
Bing ChenInstitute of Infectious Diseases, The Second Hospital of Tianjin Medical University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sepsis is a life-threatening syndrome caused by an imbalance in the inflammatory response to an infection that can lead to a high mortality rate. Methods: The serum immunoglobulin G Results: We identified that the fucosylation level was significantly decreased in patients. Importantly, bisecting GlcNAc, sialylation, and galactosylation have different levels between sepsis and control groups. In addition, the AUC values of the SOFA score combined with GP4, GP5, and GP9 were 0.76 (95%CI: 0.61 to 0.90), 0.58 (95%CI: 0.40 to 0.7) and 0.57 (95%CI: 0.38 to 0.76). The AUC value of the SOFA score combined with GP4 and GP7 was 0.85 (95%CI: 0.76 to 0.93) in predicting in-hospital mortality in patients with sepsis. Conclusions: Immunoglobulin G

Indexed as

BiomarkersEscherichia coli InfectionsImmunoglobulin GPolysaccharidesSepsisAgedFemaleFucoseGlycomicsHospitalsHumansIntensive Care UnitsMaleMiddle AgedPrognosisBiomarkersFucoseImmunoglobulin GPolysaccharidesbiomarkerEscherichia coliIgG glycosylationmortalitysepsis

Identifiers

PMID40165956
PMCPMC11955649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.